Biolex Therapeutics of Pittsboro closed on a $30 million Series C financing led by Investor Growth Capital of New York and including two other new investors, JP Morgan Securities and Easton Capital

BT Catalyst, July-August, 2007

Biolex Therapeutics of Pittsboro closed on a $30 million Series C financing led by Investor Growth Capital of New York and including two other new investors, JP Morgan Securities and Easton Capital, as well as existing shareholders including Quaker BioVentures, Polaris Venture Partners, Intersouth Partners, Mitsui & Co.

Venture Partners, Johnson & Johnson Development Corporation and Dow Venture Capital. The funds will be used primarily to advance Biolex's lead drug candidate Locteron into phase 3 clinical development in hepatitis C, and to advance the company's other drug candidates.

COPYRIGHT 2007 North Carolina Biotechnology Center
COPYRIGHT 2008 Gale, Cengage Learning

 

BNET TalkbackShare your ideas and expertise on this topic

Please add your comment:

  1. You are currently: a Guest |
  2.  

Basic HTML tags that work in comments are: bold (<b></b>), italic (<i></i>), underline (<u></u>), and hyperlink (<a href></a)

White Papers, Webcasts, and Resources

advertisement
CXO UnpluggedSmart Business interviews on BNET

See and hear how senior level executives across the Asia Pacific are developing smart business ideas across a variety of sectors. The focus is on the future, and on how businesses need to evolve.

advertisement
  • Click Here
  • Click Here
  • Click Here
advertisement

Content provided in partnership with Thompson Gale